<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="10077">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02112305</url>
  </required_header>
  <id_info>
    <org_study_id>EC 104/2557</org_study_id>
    <nct_id>NCT02112305</nct_id>
  </id_info>
  <brief_title>Compare Efficacy Nebulized and Intravenous Magnesium Sulphate in Thai Children</brief_title>
  <official_title>Comparison Efficacy of Nebulized Magnesium Sulphate to Intravenous Magnesium Sulphate in Children With Severe Acute Asthma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Queen Sirikit National Institute of Child Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Queen Sirikit National Institute of Child Health</source>
  <oversight_info>
    <authority>Thailand: Ministry of Public Health</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether nebulized magnesium sulphate is effective
      in the treatment of acute severe asthma when comparison with intravenous magnesium sulphate
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Intervention: At randomization eligible patients were allocated to receive 2.5ml of isotonic
      magnesium sulphate (150 mg,245 mmol/L) on three occasional at 20 minutes interval or
      standard treatment 50 mg/kg intravenous magnesium sulphate. The asthma severity score was
      record at 0,20,40,60,120,180,240 minutes post randomization. Adverse event were assessed at
      each assessment point. Patients were followed up until discharge from hospital to collect
      secondary outcome data.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2014</start_date>
  <completion_date type="Anticipated">December 2014</completion_date>
  <primary_completion_date type="Anticipated">December 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Asthma severity score</measure>
    <time_frame>60 minute</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Length of stay in the hospital</measure>
    <time_frame>within 2 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Acute Severe Asthma</condition>
  <arm_group>
    <arm_group_label>isotonic magnesium sulphate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2.5 ml of isotonic magnesium sulphate (150 mg, 245 mmol/L) on three occasional at 20 minutes interval</description>
  </arm_group>
  <arm_group>
    <arm_group_label>50% magnesium sulphate</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>magnesium sulphate 50mg/kg/dose intravenous drip in 20 minutes for one dose</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>isotonic magnesium sulphate</intervention_name>
    <arm_group_label>isotonic magnesium sulphate</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>50% magnesium sulphate</intervention_name>
    <arm_group_label>50% magnesium sulphate</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Children age 2-15 years presenting with severe asthma or persistent wheeze without
             responding to conventional therapy

        Exclusion Criteria:

          -  chronic lung disease

          -  history of adverse reaction form magnesium sulphate

          -  life threatening condition
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>15 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tassalapa Daengsuwan, Pediatrician</last_name>
    <role>Study Director</role>
    <affiliation>Queen Sirikit National Institute of Child Health</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Queen Sirikit National Institute of Child Health</name>
      <address>
        <city>Bangkok</city>
        <zip>10400</zip>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tassalapa Deangsuwan, Pediatrician</last_name>
      <email>tassalapa@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Thailand</country>
  </location_countries>
  <results_reference>
    <citation>Powell CV, Kolamunnage-Dona R, Lowe J, Boland A, Petrou S, Doull I, Hood K, Williamson PR; MAGNETIC study group. MAGNEsium Trial In Children (MAGNETIC): a randomised, placebo-controlled trial and economic evaluation of nebulised magnesium sulphate in acute severe asthma in children. Health Technol Assess. 2013 Oct;17(45):v-vi, 1-216. doi: 10.3310/hta17450.</citation>
    <PMID>24144222</PMID>
  </results_reference>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 9, 2014</lastchanged_date>
  <firstreceived_date>April 4, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Queen Sirikit National Institute of Child Health</investigator_affiliation>
    <investigator_full_name>Tassalapa Daengsuwan</investigator_full_name>
    <investigator_title>medical doctor</investigator_title>
  </responsible_party>
  <keyword>Magnesium sulphate nebulized</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Asthma</mesh_term>
    <mesh_term>Status Asthmaticus</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Magnesium Sulfate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
